Aug 5, 2022
Nishizuka gave a talk “Clinical implementation — somatic mutation as a tumor marker”at 2nd TOLIC Healthtech Device Forum/Healthtech Device Show.
Aug 5, 2022
Abe wins Excellent Award in the Student Research Contest at 2nd TOLIC Healthtech Device Forum/Healthtech Device Show for “Relapse prediction of bladder cancer using diigital PCR mutation monitoring from urine pellet DNA”.
Jul 31, 2022
Nishizuka lab was introduced in Iwate Medical University doctor’s association periodicals (No. 135).
Jul 22, 2022
Nishizuka gave a talk “A new monitoring clinical examination for cancer relapse using circulating tumor DNA” as a luncheon seminar sponsored by LSI Medience/Finggal Link at 77th The General Meeting of the Japanese Society of Gastrointestinal Surgery (Yokohama).
Jul 16, 2022
Nishizuka gave a talk “Somatic mutations as tumor marker” as a luncheon seminar sponsored by MSD at 94th Semi-Annual Meeting of the Japanese Society of Pathology Tohoku Niigata (Morioka, Japan).
Jul 15, 2022
Nishizuka gave a talk about how digital PCR will enable our research to Thermo Fisher Scientific Genetic Science Group employees in Asia Pacific Japan region.
Jul 7, 2022
Jun 7, 2022
Jun 4, 2022
Our recent research was presented at Gantokai (annual meeting for surgeons).
May 12, 2022
Iwate Nippo introduces the paper by Koizumi et al published inJournal of the National Cancer Institute. See details
Apr 19, 2022
Apr 15, 2022
Apr 5, 2022
Apr 1, 2022
Iwate Medical University Hospital starts OTS-Assay. The OTS-Assay uses a patented technology from Nishizuka lab.
Mar 22, 2022
New Nishizuka Lab website released designed by Sooooofa Design Desk, Inc.
Feb 25, 2022
Quantdetect, Inc. receives Grand Prize for the 19th Iwate Industry-Academia Collaboration Promotion Council (Liaison-I) sponsored by the Kita-Nippon Bank, Ltd. and the Bank of Iwate, Limited. Nishizuka lab is a collaborative laboratory of this project.
Jan 21, 2022
Dr. Nishizuka had a presentation at 14th Iwate Cancer Forum on Iwate Nippo.
Last Updated : 2022.06.13
Our patient opt-out policy permits participants to choose whether they want to use their personal information and specimens provided for our medical research. According to the policy of the Japanese Government, patients or people acting as their proxies have the right to alter the opt-out choice they made when giving informed consent for the medical research. We are currently announcing the above protocols for the opt-out opportunities. Please note, however, that we may not be able to identify individuals once their personal information and specimens provided for our medical research have been anonymously processed.